All therapiesEvidence snapshot 2026-10-13
Weight & glucose

Maridebart cafraglutide (MariTide)

Activates GLP-1 receptors and blocks GIP receptors through a peptide–antibody conjugate.

GLP-1s & metabolic therapies

At a glance

Selected evidence in this atlas
Studied use & population

Adults with obesity/overweight without type 2 diabetes

Study context
Approval & development

Investigational; MARITIME phase 3 program underway

Status & indications
Selected efficacy evidence

16.2% reported weight loss · 2.5% loss with placebo · 52 weeks

MariTide phase 2 obesity cohort · Phase 2 · peer-reviewed · 420 mg every 4 weeks after 12-week dose escalation · Regardless of stopping treatment

Evidence & limitations
Important safety context

GI adverse events predominated; dose escalation improved tolerability.

Safety context
Next milestone

A next milestone is not summarized for this therapy.

Milestone details

Study results apply to their own population, dose and analysis. They do not establish a ranking between therapies.

Evidence in the atlas

2 results

Each result belongs to its own study population, dose and analysis. Open a result for its chart, comparator, safety findings and limitations.

Weight loss

MariTide phase 2 obesity cohort

16.2% reported weight loss · 2.5% loss with placebo · 52 weeks

420 mg every 4 weeks after 12-week dose escalation

Adults with obesity/overweight without type 2 diabetes

Intention-to-treat approach; regardless of adherence. 465-person obesity cohort; separate 127-person diabetes cohort excluded. Investigational; MARITIME phase 3 program underway

Safety context

GI adverse events predominated; dose escalation improved tolerability.

Limitations: Dose-finding trial, not direct comparison with marketed drugs. Highest efficacy estimate across arms is 19.9%, with 2.6% placebo.

Explore result Compare study Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial · 2025-06-23
Glucose control

Obesity–diabetes cohort

1.5 percentage-point HbA1c decrease · 0.1 pp increase with Placebo · 52 weeks

420 mg every 4 weeks, without dose escalation

Adults with obesity and type 2 diabetes

Treatment-policy estimate, including discontinuation; HbA1c was a secondary outcome.

Safety context

Gastrointestinal events were common. Titration was not used in this diabetes cohort; tolerability results from titrated obesity-only arms are not interchangeable.

Limitations: Diabetes cohort only: 127 of the 592 participants. The 1.5 pp policy estimate differs from the published visit curve.

Explore result Compare study MariTide phase 2, Table 2 and Figure 1D · 2025-06-23

Biology & identity

Status in this atlas: Investigational; MARITIME phase 3 program underway

Hormone activity

GLP-1Activates receptorsGIPBlocks receptors

Activates GLP-1 receptors and blocks GIP receptors through a peptide–antibody conjugate.

What do these hormones do? GLP-1 · GIP

Investigational; no approved trade name identified as of 2026-09-13. MariTide is Amgen's development shorthand for maridebart cafraglutide (formerly AMG 133), not an approved brand.

Amgen · Developer and sponsor of the MariTide program, previously AMG 133.

Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.

The molecule

Activates GLP-1 receptors and blocks GIP receptors through a peptide–antibody conjugate.
Structure not yet verified

Structure not verified

Activates GLP-1 receptors and blocks GIP receptors through a peptide–antibody conjugate.

Shown: Peptide–antibody conjugate

An exact-drug structure was not verified in this review. The named PubChem lookup did not return a compound record; no related hormone or analogue is substituted.

Maridebart cafraglutide (MariTide)

Development timeline

Next milestone

A next milestone is not summarized for this therapy. This does not mean development has ended.

Development history3 selected milestones

Maridebart cafraglutide (MariTide) · compound history across indications

Selected milestones only. Earlier studies may be missing; the first listed date should not be interpreted as the start of development.

  1. MARITIME enrollment confirmed

    Amgen reported that MARITIME-1 and MARITIME-2 were enrolling adults with obesity or overweight without and with type 2 diabetes.

    Source

  2. 52-week phase 2 results published

    Amgen presented the monthly-dosing phase 2 study at ADA alongside publication in the New England Journal of Medicine.

    Source
  3. Announcement

    MariTide registers a home-autoinjector study

    Amgen plans 230 adults in an open-label study of successful home self-injection, rather than a comparative weight-loss result. October 28 estimated start; June 16, 2027 estimated primary completion; no public-result date.

    Source

Selected sources checked Oct 13, 2026. This is not an exhaustive history.